| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | MK-3222, SCH900222 |
| Cas No. | |
| Clonality | |
| Expression System | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Tildrakizumab (HV466026) is a research-grade recombinant antibody targeting SGRF. Produced in mammalian cells with native-like glycosylation. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Specifications
| Host Species | Humanized |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Target | SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | Q9NPF7 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
Interleukin-23 subunit alpha (IL23A) is a ~20 kDa protein. Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity. Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4. This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A. In turn, participates in the early and effective intracellular bacterial clearance. Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells. IL23A is the therapeutic target of guselkumab (Tremfya).
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Oppmann, B. et al. (2000) Immunity 13, 715-25. PMID: 11114383
2. Bloch, Y. et al. (2018) Immunity 48, 45-58.e6. PMID: 29287995
3. Sun, R. et al. (2020) Cellular and molecular gastroenterology and hepatology 10, 673-697. PMID: 32474165
4. Glassman, CR. et al. (2021) Cell 184, 983-999.e24. PMID: 33606986
5. Parham, C. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 168, 5699-708. PMID: 12023369
6. Wilson, NJ. et al. (2007) Nature immunology 8, 950-7. PMID: 17676044
